NPNicolas Philippe

Nicolas Philippe

*This is an algorithmically generated author record based on publicly available information.

Nicolas Philippe has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integration of Machine Learning-Based Pathogenicity Prediction and Phenotype Matching Improves Variant Prioritization in Rare Clinical Testing

    by Jiri Ruzicka, Jean-Marie Ravel, Jérôme Audoux, Alexandre Boulat, Julien Thévenon, Kévin Yauy, Marine Dancer, Laure Raymond, Yannis Lombardi, Nicolas Philippe, et al.

    Genome and exome sequencing have become central to diagnosing rare hereditary diseases, but each test returns thousands of variants that a clinical scientist must review by hand to find the one responsible for the patient’s condition. This manual interpretation is the main bottleneck in clinical genomics. To reduce it, we developed DiagAI, a machine-learning system that ranks the variants found in a patient and returns a short list of the most likely causal candidates. DiagAI combines three sources of evidence: a pathogenicity score from the Universal Pathogenicity Predictor (UP2), a model we trained to estimate how damaging a variant is on the five-tier scale of the American College of Medical Genetics and Genomics (ACMG); a phenotype-matching score from PhenoGenius, which weighs how well a gene’s known clinical features match the patient’s symptoms (encoded as Human Phenotype Ontology, or HPO, terms); and expert rules covering inheritance pattern and sequencing quality. We evaluated DiagAI on 966 exomes from adults investigated for kidney disease of unknown cause, of which 196 had a confirmed genetic diagnosis. We first tested UP2 on its own by ranking 62 confirmed disease-causing missense variants that were absent from its training data: UP2 placed the causal variant within the top 100 candidates in 87% of cases, compared with 61% for the widely used tool REVEL. Across the 196 diagnosed exomes, the full DiagAI shortlist contained the causal variant in 94.9% of cases when the patient’s symptoms were provided and in 90.8% when they were not, with a typical shortlist of about 10 variants. When symptoms were provided, the single top-ranked variant was the correct diagnosis in 74% of cases, versus 42% without symptoms, exceeding the performance of the established tools Exomiser and AI-MARRVEL on the same cohort. DiagAI produces compact, accurate shortlists that can reduce the manual interpretation workload as diagnostic sequencing volumes continue to grow.


  • Développement de méthodes et d'algorithmes pour la caractérisation et l'annotation des transcriptomes avec les séquenceurs haut débit.

    by Nicolas Philippe

    Depuis leur apparition, les séquenceurs haut débit ont révolutionné l'étude des transcriptomes à l'échelle du génome. En effet, ils offrent la possibilité de générer des millions, voire des milliards de séquences, appelées reads. Des nouvelles approches transcriptomiques, telles que la Digital Gene Expression (DGE) et le RNA-Sequencing (RNA-Seq), permettent aujourd'hui de répertorier, de quantifier, voire reconstruire tous les transcrits d'une cellule, même les plus rares. Parmi ce type de transcrits se trouvent des ARN non-codants régulateurs ; des variants d'épissages créateurs de protéines ; et aussi des chimères (par fusion de gènes ou trans-épissage). La caractérisation de l'ensemble de ces transcrits représente un réel défi algorithmique, mais suscite aussi un défi biologique car certains peuvent être impliqués dans de nombreux processus cellulaires physiologiques et pathologiques et sont fréquemment décrits dans les cancers.Dans ce travail, nous proposons des algorithmes et des méthodes pour la caractérisation et l'annotation des transcriptomes. Tout d'abord, nous proposons une étude statistique sur la DGE afin d'évaluer l'impact des erreurs de séquences lors de l'analyse des reads. À partir de cette analyse, nous avons développé un pipeline d'annotation pour la DGE. Par le biais de ce premier travail, nous avons pu démontrer que de nombreuses informations étaient partagées entre les reads. Cela nous a amené à concevoir la structure d'indexation Gk arrays qui permet d'organiser une quantité massive de reads de façon à pouvoir interroger rapidement la structure sous forme de requêtes. Enfin, en s'appuyant sur les Gk arrays, nous avons développé CRAC qui est un logiciel spécialisé dans le traitement du RNA-Seq. En intégrant sa propre phase de mapping, CRAC est capable de distinguer les phénomènes biologiques des erreurs de séquences. Ilpermet notamment l'identification de chimères qui sont souvent très faiblement exprimées dans un transcriptome et sont par nature complexe à détecter avec des parties localisées à différents endroits sur le génome.

  • Open Access

    Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

    by Pascal Pujol, Kevin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daurès, Frédérique Penault Llorca, Frédéric Thomas, Kevin Hughes, Clare Turnbull, et al.

    Background: Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting. Therefore, we need to reassess the frequency of gBRCA1 and gBRCA2 in order to redefine the criteria for women and tumor phenotype that should be tested. Objective: We studied the relative distribution of gBRCA1 and gBRCA2 in unselected populations of women with breast cancer and in unaffected individuals. We also analyzed the proportion of estrogen receptor (ER)-positive (ER+) tumors in unselected breast cancer patients with gBRCA. Design: We performed a meta-analysis of studies of unselected breast cancer that analyzed the relative contribution of gBRCA1 versus gBRCA2 among unselected breast cancer cases in gBRCA carriers. We then performed a meta-analysis of gBRCA carriage in unaffected individuals from genome-wide population studies, the gnomAD databank, and case–control studies. Results: The BRCA2 gene was involved in 54% of breast cancer cases in unselected patients with gBRCA (n = 108,699) and 60% of unaffected individuals (n = 238,973) as compared with 38% of the largest gBRCA family cohort (n = 29,700). The meta-analysis showed that 1.66% (95% CI 1.08–2.54) and 1.71% (95% CI 1.33–2.2) of unselected breast cancer patients carried gBRCA1 and gBRCA2, respectively. In a population of unaffected individuals, the frequency of heterozygosity for gBRCA1 and gBRCA2 was estimated at 1/434 and 1/288, respectively. Nearly 0.5% of unaffected individuals in the studied populations carried a gBRCA. Carriage of a gBRCA was 2.5% for patients with ER+ tumors (95% CI 1.5–4.1) and 5.7% (95% CI 5.1–6.2) for those with ER- tumors. Overall, 58% of breast tumors occurring in women carrying a gBRCA were ER+ (n = 86,870). Conclusions: This meta-analysis showed that gBRCA2 carriage is predominant in unselected breast cancer patients and unaffected individuals. ER+ tumors among women with gBRCA-related breast cancer are predominant and have been underestimated. Because PARPi agents improve progression-free survival with ER+ gBRCA breast cancer in most clinical trials, breast cancer should be considered, regardless of ER status, for BRCA1/2 screening for therapeutic purposes.


  • Open Access

    SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines

    by Jérôme Audoux, Mikaël Salson, Christophe F. Grosset, Sacha Beaumeunier, Jean-Marc Holder, Thérèse Commes, Nicolas Philippe

    The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters. Users face an increasingly complex task in understanding which bioinformatic tools are best for their specific needs and how they should be configured. In order to provide some answers to these questions, we investigate the performance of leading bioinformatic tools designed for RNA-Seq analysis and propose a methodology for systematic evaluation and comparison of performance to help users make well informed choices. To evaluate RNA-Seq pipelines, we developed a suite of two benchmarking tools. SimCT generates simulated datasets that get as close as possible to specific real biological conditions accompanied by the list of genomic incidents and mutations that have been inserted. BenchCT then compares the output of any bioinformatics pipeline that has been run against a SimCT dataset with the simulated genomic and transcriptional variations it contains to give an accurate performance evaluation in addressing specific biological question. We used these tools to simulate a real-world genomic medicine question s involving the comparison of healthy and cancerous cells. Results revealed that performance in addressing a particular biological context varied significantly depending on the choice of tools and settings used. We also found that by combining the output of certain pipelines, substantial performance improvements could be achieved. Our research emphasizes the importance of selecting and configuring bioinformatic tools for the specific biological question being investigated to obtain optimal results. Pipeline designers, developers and users should include benchmarking in the context of their biological question as part of their design and quality control process. Our SimBA suite of benchmarking tools provides a reliable basis for comparing the performance of RNA-Seq bioinformatics pipelines in addressing a specific biological question. We would like to see the creation of a reference corpus of data-sets that would allow accurate comparison between benchmarks performed by different groups and the publication of more benchmarks based on this public corpus. SimBA software and data-set are available at http://cractools.gforge.inria.fr/softwares/simba/ .